Among the many ways Trump has shattered White House norms, his impulsive public communications rank among the most consequential. By inspiring investors or spooking them, his...Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
In a private call with Morgan Stanley clients on Wednesday, research analyst Adam Jones, a long-time Tesla bull, said it's extremely unlikely that big tech firms like Apple or...Technologyread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
Talk about 5G is everywhere right now, from the trade war with China to the ban on Huawei. Here's what 5G is and why it matters.Technologyread more
"Target's gutsy decision to make its stores the centerpiece of its fulfillment system has turned out to be a brilliant move," Jim Cramer says.Mad Money with Jim Cramerread more
A slew of retail earnings the past two weeks makes it clear that while Americans continue to shop, they aren't ringing registers at department stores.Retailread more
Stocks that would benefit from a federal infrastructure spending program fell after President Trump ended a meeting on infrastructure spending with Democratic leaders.Market Insiderread more
The interaction, witnessed by a senior administration official, followed President Donald Trump's abrupt exit out of a meeting with Democratic congressional leaders.Politicsread more
A team of international scientists announced a medical breakthrough in Singapore on Thursday that could improve millions of lives: existing anti-malaria drugs have the ability to treat Parkinson's disease, according to new research by Nanyang Technological University (NTU) and Harvard Medical School's McLean Hospital.
Parkinson's is a fatal degenerative disorder that impacts the central nervous system, causing people to lose control of motor movements. Seven to ten million people worldwide are currently diagnosed with the disease and there is no known cure.
After screening over 1000 drugs approved by the U.S. Food and Drug Administration, the scientists discovered that chloroquine and amodiaquine—two common anti-malaria treatments—could bind and activate a class of proteins in the brain vital to fight Parkinson's. Called Nurr1, these proteins protect the brain's ability to generate dopamine neurons, which are essential to the body's movement of muscles. Patients with the disease gradually cease the production of dopamine neurons, thus losing motor control.
"Backed by various lines of scientific evidence, Nurr1 is known to be a potential drug target to treat Parkinson's. Despite great efforts from pharmaceutical companies and academia, no one has managed to find a molecule which can directly bind to it and activate it, except for us," said Professor Kwang-Soo Kim from Harvard's McLean Hospital.
In laboratory tests on rats, the team found that by activating Nurr1, the rats with Parkinson's appeared to have their symptoms alleviated.
Current treatment for the disorder is aimed at replenishing dopamine levels via medication or surgical methods but while these methods improve mobility functions in the early stage, they cannot slow down or stop the disease, Professor Kim explained.
"Our research shows that existing drugs can be repurposed to treat other diseases and once several potential drugs are found, we can redesign them to be more effective in combating their targeted diseases while reducing the side effects," said NTU Associate Professor Yoon Ho Sup.
Parkinson's typically affects people over the age of 60, according to the National Institute of Neurological Disorders and Stroke (NINDS), and as countries battle with rapidly ageing populations, cases of neurodegenerative diseases like Parkinson's are widely expected to rise.
The scientists are now aiming to design better drugs for the disease by modifying chloroquine and amodiaquine with the hope of carrying out clinical trials soon.